The research progress of N6-methyladenosine methyltransferase METTL3 in urologic tumors
10.3781/j.issn.1000-7431.2023.2306-0260
- VernacularTitle:N6-甲基腺嘌呤甲基转移酶METTL3在泌尿系统肿瘤中的研究进展
- Author:
Zhengsheng LI
1
;
Yimeng CHEN
;
Shuchen ZHAO
;
Dong XUE
Author Information
1. 常州市第一人民医院泌尿外科,江苏 常州 213003
- Keywords:
Urologic tumor;
N6-methyladenosine;
Methyltransferase
- From:
Tumor
2023;43(12):971-983
- CountryChina
- Language:Chinese
-
Abstract:
N6-methyladenosine(m6A)represents one of the most abundant modifications in eukaryotes RNA.M6A modification is catalyzed and modified by m6A methyltransferases and demethylases.The fates of m6A-modified mRNAs rely on the functions of distinct"reader"proteins that recognize them,which may affect the splicing,processing,translation or degradation of the target mRNAs.Methyltransferase-like 3(METTL3)is a catalytic core component of m6A methyltransferase compound,whose abnormal expression could lead to disordered m6A modifications and further influence the proliferation,invasion,migration and drug resistance of tumor cells.As the functions of METTL3 have been explored in depth,METTL3 inhibitors have become research hotspots.Therefore,this review focus on the different target molecules and downstream signaling pathways affected by METTL3 with the assistance of different readers in the tumorigenesis and progression of urologic tumors,and summarizes the research progress of METTL3 inhibitors,in the hope to provide insights for the prevention,diagnosis and treatment of tumors.
